The field finally seems on the cusp of succeeding.
“You’re seeing a convergence of technology now, so we can actually run large-scale clinical studies to get the data to prove odor analysis has real utility,” said Billy Boyle, co-founder and president of operations at Owlstone, a manufacturer of chemical sensors in Cambridge, England.
Mr. Boyle, an electronics engineer, formed the company with two friends in 2004 to develop sensors to detect chemical weapons and explosives for customers, including the United States government. But when Mr. Boyle’s girlfriend and eventual wife, Kate Gross, was diagnosed with colon cancer in 2012, his focus shifted to medical sensors, with an emphasis on cancer detection.
Ms. Gross died last year. That she might still be alive if her cancer had been detected earlier, Mr. Boyle said, continues to be a “big motivator.”
Owlstone has raised $23.5 million to put its odor analysis technology into the hands of clinicians. Moreover, Britain’s National Health Service is funding a 3,000-subject clinical trial to test Owlstone’s sensor to diagnose lung cancer.
The sensor is a silicon chip stacked with various metal layers and tiny gold electrodes. While it looks like your mobile phone’s SIM card, it works like a chemical filter.
The molecules in an odor sample are first ionized — given a charge — and then an electric current is used to move only chemicals of diagnostic interest through the channels etched in the chip, where they can be detected.
“You can program what you want to sniff out just by changing the software,” Mr. Boyle said. “We can use the device for our own trials on colorectal cancer, but it can also be used by our partners to look for other things, like irritable bowel disease.”
The company also is conducting a 1,400-subject trial, in collaboration with the University of Warwick, to detect colon cancer from urine samples, and is exploring whether its chips can help determine the best drugs for asthma patients by sorting through molecules in their breath.
A similar diagnostic technology is being developed by an Israeli chemical engineer, Hossam Haick, who was also touched by cancer.
“My college roommate had leukemia, and it made me want to see whether a sensor could be used for treatment,” said Mr. Haick, a professor at Technion-Israel Institute of Technology in Haifa. “But then I realized early diagnosis could be as important as treatment itself.”
His smelling machine uses an array of sensors composed of gold nanoparticles or carbon nanotubes. They are coated with ligands, molecular receptors that have a high affinity for certain biomarkers of disease found in exhaled breath.
Once these biomarkers latch onto the ligands, the nanoparticles and nanotubes swell or shrink, changing how long it takes for an electrical charge to pass between them. This gain or loss in conductivity is translated into a diagnosis.
“We send all the signals to a computer, and it will translate the odor into a signature that connects it to the disease we exposed to it,” Mr. Haick said.
With artificial intelligence, he said, the machine becomes better at diagnosing with each exposure. Rather than detecting specific molecules that suggest disease, however, Mr. Haick’s machine sniffs out the overall chemical stew that makes up an odor.
It’s analogous to smelling an orange: Your brain doesn’t distinguish among the chemicals that make up that odor. Instead, you smell the totality, and your brain recognizes all of it as an orange.
Mr. Haick and his colleagues published a paper in ACS Nano last December showing that his artificially intelligent nanoarray could distinguish among 17 different diseases with up to 86 percent accuracy.
There were a total of 1,404 participants in the trial, but the sample sizes for each disease were quite small. And the machine was better at distinguishing among some diseases than others.
In the United States, a team of researchers from the Monell Chemical Senses Center and the University of Pennsylvania received an $815,000 grant in February from the Kleburg Foundation to advance work on a prototype odor sensor that detects ovarian cancer in samples of blood plasma.
The team chose plasma because it is somewhat less likely than breath or urine to be corrupted by confounding factors like diet or environmental chemicals, including cleaning products or pollution.
Instead of ligands, their sensors rely on snippets of single-strand DNA to do the work of latching onto odor particles.
“We are trying to make the device work the way we understand mammalian olfaction works,” said Charlie Johnson, director of the Nano/Bio Interface Center at the University of Pennsylvania, who is leading the fabrication effort. “DNA gives unique characteristics for this process.”
In addition to these groups, teams in Austria, Switzerland and Japan also are developing odor sensors to diagnose disease.
“I think the fact that you’re seeing so much activity both in commercial and academic settings shows that we’re getting a lot closer,” said Cristina Davis, a biomedical engineer and professor at the University of California, Davis, who also is helping to develop an odor sensor to diagnose disease.
“My estimate is it’s a three- to five-year time frame” before such tools are available to clinicians, she added.
The researchers may be competing intensely, but all see possibilities for saving lives.
“There’s a lot of good work going on out there,” Mr. Johnson said. “It will be interesting to see who comes out on top.”